Levocetirizine 5 mg + Ambroxol SR 75 mg + Montelukast 10 mg Uncoated Bilayered Tablet

Levocetirizine 5 mg + Ambroxol SR 75 mg + Montelukast 10 mg Uncoated Bilayered Tablet is a uncoated bilayered tablet formulated with Levocetirizine 5 mg + Ambroxol SR 75 mg + Montelukast 10 mg. The active ingredient profile is Levocetirizine; Ambroxol; Montelukast, placing the product in the antihistamine + mucolytic + leukotriene receptor antagonist combination category. The formulation combines antihistamine and leukotriene-modifying therapy with Ambroxol, a mucolytic/expectorant component intended to support mucus clearance. The modified-release designation indicates a controlled release presentation and must be described and administered exactly as stated in the approved product literature. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.